Company attributes
Location
B2X
CEO
Date Incorporated
December 12, 2016
Number of Employees (Ranges)
1 – 10
Email Address
bhadida@exeliombio.com0
Full Address
67 rue des Godrans 21000 Dijon France0
24 rue du Faubourg Saint-Jacques, 75014 Paris (Paris Biotech Santé, Cochin)0
Investors
Founded Date
2016
Total Funding Amount (USD)
11,627,725
Latest Funding Round Date
October 21, 2025
Latest Funding Type
Country
Headquarters
Other attributes
Company Operating Status
Active
Latest Funding Round Amount (USD)
3,300,000
Exeliom Biosciences develops single bacterial strain drug candidates to deliver microbiome-based therapeutics (also known as Live Biotherapeutics) for the treatment of immune-mediated diseases, with specific focus on inflammatory bowel diseases (IBD), and Crohn’s Disease.
Timeline
No Timeline data yet.
Funding Rounds
Products
Acquisitions
SBIR/STTR Awards
Patents
Further Resources
No Further Resources data yet.
